{
  "variants": [
    {
      "variant": "M26I",
      "gene": "DJ-1",
      "protein_change": "Met26Ile",
      "variant_string_id": "DJ-1_M26I",
      "steps": [
        {
          "step": "Step 1: Define the disease mechanism",
          "details": "DJ-1's cytoprotective role is disrupted by M26I, leading to loss of DJ-1 protein and failure to suppress ASK1 activity."
        },
        {
          "step": "Step 2: Applicability of assays",
          "details": "Protein expression and cytoprotection assays are directly relevant to the disease mechanism."
        },
        {
          "step": "Step 3: Validity of assays",
          "details": "Controls (knockout mice, wild-type) and replicates are used, meeting Step 3a."
        },
        {
          "step": "Step 4: Apply evidence to individual variant interpretation",
          "details": "No OddsPath calculation, but functional impairment is clear. Assuming at least 11 control variants, strength is PS3_moderate."
        }
      ],
      "strength": "PS3_moderate"
    },
    {
      "variant": "C106A",
      "gene": "DJ-1",
      "protein_change": "Cys106Ala",
      "variant_string_id": "DJ-1_C106A",
      "steps": [
        {
          "step": "Step 1: Define the disease mechanism",
          "details": "C106A abolishes ASK1 binding and cytoprotective activity, directly disrupting DJ-1's protective role."
        },
        {
          "step": "Step 2: Applicability of assays",
          "details": "Binding and cytoprotection assays are directly relevant to the disease mechanism."
        },
        {
          "step": "Step 3: Validity of assays",
          "details": "Controls (wild-type, other mutants) and replicates are used, meeting Step 3a."
        },
        {
          "step": "Step 4: Apply evidence to individual variant interpretation",
          "details": "No OddsPath calculation, but functional impairment is clear. Assuming at least 11 control variants, strength is PS3_moderate."
        }
      ],
      "strength": "PS3_moderate"
    },
    {
      "variant": "C46A",
      "gene": "DJ-1",
      "protein_change": "Cys46Ala",
      "variant_string_id": "DJ-1_C46A",
      "steps": [
        {
          "step": "Step 1: Define the disease mechanism",
          "details": "C46A retains cytoprotective activity, indicating no disruption to DJ-1's protective role."
        },
        {
          "step": "Step 2: Applicability of assays",
          "details": "Cytoprotection assays are relevant, but no direct pathogenic effect is shown."
        },
        {
          "step": "Step 3: Validity of assays",
          "details": "Controls (benign variants) are used, meeting Step 3c."
        },
        {
          "step": "Step 4: Apply evidence to individual variant interpretation",
          "details": "Retains cytoprotective activity, suggesting benign classification. Strength: BS3_moderate."
        }
      ],
      "strength": "BS3_moderate"
    },
    {
      "variant": "C53A",
      "gene": "DJ-1",
      "protein_change": "Cys53Ala",
      "variant_string_id": "DJ-1_C53A",
      "steps": [
        {
          "step": "Step 1: Define the disease mechanism",
          "details": "C53A retains cytoprotective activity, indicating no disruption to DJ-1's protective role."
        },
        {
          "step": "Step 2: Applicability of assays",
          "details": "Cytoprotection assays are relevant, but no direct pathogenic effect is shown."
        },
        {
          "step": "Step 3: Validity of assays",
          "details": "Controls (benign variants) are used, meeting Step 3c."
        },
        {
          "step": "Step 4: Apply evidence to individual variant interpretation",
          "details": "Retains cytoprotective activity, suggesting benign classification. Strength: BS3_moderate."
        }
      ],
      "strength": "BS3_moderate"
    },
    {
      "variant": "C106DD",
      "gene": "DJ-1",
      "protein_change": "Cys106DD",
      "variant_string_id": "DJ-1_C106DD",
      "steps": [
        {
          "step": "Step 1: Define the disease mechanism",
          "details": "C106DD non-covalently binds ASK1 and confers partial cytoprotection, indicating reduced but not absent function."
        },
        {
          "step": "Step 2: Applicability of assays",
          "details": "Binding and cytoprotection assays are relevant to the disease mechanism."
        },
        {
          "step": "Step 3: Validity of assays",
          "details": "Controls (wild-type, other mutants) and replicates are used, meeting Step 3a."
        },
        {
          "step": "Step 4: Apply evidence to individual variant interpretation",
          "details": "Partial cytoprotection suggests benign classification. Strength: BS3_supporting."
        }
      ],
      "strength": "BS3_supporting"
    }
  ]
}